Study Comparing Pulsed-Dye Laser and Timolol Gel to Prevent Growth of Hemangioma Birthmarks in Newborns

What this Trial Is About

This research aims to evaluate whether pulsed dye laser treatment or timolol maleate 0.5% gel can help infants with hemangiomas, which are common birthmarks caused by clusters of blood vessels. The study also examines the safety of these treatments to ensure they do not cause too many side effects. Hemangiomas typically appear soon after birth and often disappear on their own, but some require treatment due to potential health risks or disfigurement. Infants will be randomly assigned to one of three groups one receiving a series of up to six weekly or semi-weekly pulsed dye laser treatments using an FDA-cleared 595-nm laser device another receiving twice daily topical applications of timolol maleate 0.5% ophthalmic gel for up to six months or an observation group receiving no treatment. The laser treatments involve protective eyewear and carefully controlled laser energy, while the timolol dose is adjusted to cover the hemangioma area without excess medication. Participants will be monitored regularly with clinical assessments and digital photographs to measure hemangioma size and response over two years. Researchers will record treatment outcomes, side effects, parents cosmetic satisfaction, functional improvements, and any additional treatments needed. This follow-up period aims to determine how early treatment with laser or timolol affects hemangioma growth and complications compared to no treatment.

A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn